PTCT - PTC Therapeutics - Stock Price & Dividends

PTC Therapeutics Inc. is a biopharmaceutical company that specializes in developing and commercializing innovative medicines for patients with rare and debilitating disorders. The company's primary focus is on addressing unmet medical needs in the United States and internationally.

PTC Therapeutics has a diverse portfolio of approved products, including Translarna and Emflaza for the treatment of Duchenne muscular dystrophy, a genetic disorder that affects muscle strength and function. The company also offers Upstaza, a treatment for aromatic l-amino acid decarboxylase (AADC) deficiency, a rare genetic disorder that affects the central nervous system. Additionally, PTC Therapeutics provides Tegsedi and Waylivra for the treatment of rare diseases, as well as Evrysdi, a treatment for spinal muscular atrophy (SMA) in adults and children.

The company's development pipeline is robust, with several promising products in various stages of development. For example, Sepiapterin is being developed to treat phenylketonuria, a genetic disorder that affects the body's ability to break down protein. PTC Therapeutics is also working on its PTC518 splicing platform, which has the potential to treat Huntington's disease, a rare genetic disorder that affects the brain. Furthermore, the company is exploring ferroptosis and inflammation platforms, including vatiquinone for the treatment of Friedreich ataxia, a rare genetic disorder that affects the nervous system, and utreloxastat for the treatment of amyotrophic lateral sclerosis (ALS), a progressive neurological disease.

PTC Therapeutics partners with third-party distributors to ensure that its products reach patients in need. The company has established collaborations with several organizations, including F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. These partnerships enable PTC Therapeutics to leverage the expertise and resources of its collaborators to advance its research and development efforts.

Founded in 1998, PTC Therapeutics is headquartered in South Plainfield, New Jersey, and has a strong commitment to improving the lives of patients with rare and debilitating disorders. For more information, please visit the company's website at https://www.ptcbio.com.